证券代码：301367 证券简称：怡和嘉业 北京怡和嘉业医疗科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |----------------|--------------------------------|----------------------------------------------------------| | | | 编号：2024—009 | | | □ 特定对象调研 □ | 分析师会议 | | 投资者关系活动 | □ 媒体采访 | √ 业绩说明会（电话形式） | | 类别 | □ 新闻发布会 □ | 路演活动 | | | □ 现场参观 | | | | □ 其他 | | | 参与单位名称 | 详见附件清单 | | | 时间 | 2024 年 8 月 20 日 | | | 地点 | 电话会议 | | | 上市公司接待人 | 副总经理兼董事会秘书：杜祎程 | | | 员姓名 | 证券事务代表：刘士岩 | | | | 一、公司简要介绍 | | | | 公司 2001 年成立， | 2003 年第一台多导睡眠检测仪上市，2007 | | | 年第一台 CPAP ...

怡和嘉业（ [Table_StockNameRptType] 301367） 公司点评 24H1 业绩仍承压，静待下半年边际改善 | --- | --- | --- | --- | --- | --- | --- | |-----------------------------------------------------------------------------------------------------------|-------------------------|--------|-------|--------|-------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ...

证券代码：301367 证券简称：怡和嘉业 公告编号：2024-052 北京怡和嘉业医疗科技股份有限公司 关于举行2024年半年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 北京怡和嘉业医疗科技股份有限公司（以下简称"公司"）于 2024 年 8 月 20 日发 布了《2024 年半年度报告》及其摘要，并披露于中国证监会指定的创业板信息披露网站 巨潮资讯网（http://www.cninfo.com.cn）。 为便于广大投资者更深入全面地了解公司情况，公司定于 2024 年 8 月 26 日（星期 一）下午 15:00-16:30 在深圳证券交易所"互动易"平台"云访谈"栏目举行 2024 年半 年度网上业绩说明会。本次业绩说明会将采用网络远程的方式举行，投资者可登陆深圳 证券交易所"互动易"平台（http://irm.cninfo.com.cn），进入"云访谈"栏目参与本次业 绩说明会。 北京怡和嘉业医疗科技股份有限公司董事会 2024 年 8 月 20 日 2 为充分尊重投资者、提升交流的针对性，现就公司本次业绩说明会提前向广大投 ...

Financial Performance - The company reported a revenue of RMB 500 million for the first half of 2024, representing a 20% increase compared to the same period in 2023[5]. - The company's operating revenue for the reporting period was ¥382,167,847.68, a decrease of 48.79% compared to the same period last year[12]. - Net profit attributable to shareholders was ¥92,375,875.50, down 62.08% year-on-year[12]. - The net profit after deducting non-recurring gains and losses was ¥66,501,178.57, a decline of 69.08% compared to the previous year[12]. - Basic and diluted earnings per share were both ¥1.03, down 72.97% year-on-year[12]. - The gross profit margin for the first half of 2024 was reported at 45%, a slight improvement from 43% in the same period last year[5]. - The company reported a significant decrease in cash and cash equivalents, with a net decrease of ¥144,697,977.98 compared to an increase of ¥16,971,095.75 in the previous year, a decline of 952.61%[62]. - The company reported a total of 214.33 million yuan in related party transactions, accounting for 1.02% of the approved transaction amount[111]. Research and Development - Research and development expenses increased by 30% year-on-year, totaling RMB 50 million, focusing on innovative medical technologies[5]. - The company has established multiple R&D teams focusing on different product lines, including home non-invasive ventilators and medical respiratory diagnostic products[24]. - The company is actively involved in the research and development of advanced technologies to upgrade existing products and develop new ones[26]. - The company has implemented a research and development incentive system to encourage patent output and promote technological innovation[90]. - The company reported a significant increase in R&D personnel costs, which include salaries and various insurance fees for research staff[198]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2025[5]. - A strategic acquisition of a local competitor is expected to be finalized by Q4 2024, which will enhance the company's product portfolio[5]. - The company is actively exploring partnerships with international firms to enhance its technological capabilities and market reach[5]. - The company is focused on expanding its product portfolio to address the growing demand for respiratory therapy solutions globally[46]. - The company is exploring new market expansion strategies, aiming to enhance its competitive edge in the healthcare technology sector[181]. Product Development and Innovation - The company aims to become a global leader in respiratory health management by developing a comprehensive range of medical products[18]. - The company is developing a new generation of high-performance ventilators, currently in the design phase, aimed at expanding its product line and entering the high-end market[27]. - The company is focusing on the development of AI-integrated home medical devices, leveraging advancements in technology to enhance product innovation and market reach[33]. - The company is focused on expanding its product line with innovative medical devices to enhance treatment options for patients[48]. - The company has obtained CE certification for its non-invasive ventilators and high-flow humidified oxygen therapy devices, enhancing product competitiveness[27]. Regulatory and Compliance - The company has achieved multiple certifications including NMPA, FDA, and CE, allowing its products to enter various international markets, including the U.S. and Europe[37]. - The company is currently in the registration process for 2 domestic medical device registration projects and 17 foreign qualification certifications, with specific products including sleep apnea treatment devices and ventilation masks[41]. - The company has established a clear framework for categorizing and allocating R&D expenses, ensuring transparency and accuracy in financial reporting[198]. - The company emphasizes the importance of adhering to regulatory requirements for disclosing information related to its medical device business[200]. Corporate Governance and Shareholder Relations - The company has a clear profit distribution and cash dividend policy in compliance with regulatory requirements[104]. - The annual shareholders' meeting held on May 9, 2024, had an investor participation rate of 63.18%[95]. - The company has experienced changes in its board of directors, with resignations and appointments occurring in 2024 due to internal business adjustments[96]. - The company has a total of 10 major shareholders, with the top three holding a combined 34.80% of the shares[130]. - The company has not disclosed any other related party transactions or agreements among the major shareholders[130]. Social Responsibility and Community Engagement - The company donated respiratory treatment equipment worth 10 million CNY to over 100 county-level medical institutions in various provinces in 2023[108]. - The company has actively participated in social welfare by donating 100 oxygen machines and 400,000 CNY to support patients with pneumoconiosis in 2024[108]. - The company has been recognized for its efforts in promoting quality medical resources and enhancing grassroots medical service levels[108]. Financial Management and Investments - The company plans to use up to ¥14 billion of temporarily idle raised funds for cash management, investing in safe and liquid products[73]. - The company’s cash management strategy includes purchasing structured deposits and large-denomination certificates of deposit with a maximum investment period of 12 months[73]. - The company reported a total capital reserve of CNY 1,772,829,200, with a decrease in retained earnings of CNY 64,000,000,000 due to profit distribution[155]. - The company has made significant investments in R&D, which has led to substantial technological advancements and product iterations, positioning it favorably in the market[56]. Environmental and Ethical Practices - The company has implemented various environmental protection measures and has not faced any administrative penalties for environmental issues during the reporting period[101]. - The company emphasizes the protection of employee rights and aims to create a harmonious corporate culture[105]. - The company has not been included in the list of key pollutant discharge units and does not belong to heavily polluting industries[107].

证券代码：301367 证券简称：怡和嘉业 公告编号：2024-051 北京怡和嘉业医疗科技股份有限公司 经中国证券监督管理委员会《关于同意北京怡和嘉业医疗科技股份有限公司 首次公开发行股票注册的批复》（证监许可〔2022〕1631 号）同意注册，并经 深圳证券交易所同意，公司首次公开发行人民币普通股（A 股）股票 1,600 万股， 每股面值 1.00 元，发行价格为每股人民币 119.88 元，本次发行募集资金总额为 人民币 191,808.00 万元，扣除发行费用（不考虑前期已入损益的人民币 320.75 万元）后募集资金净额为人民币 173,826.74 万元，上述募集资金已于 2022 年 10 月 25 日划至公司指定账户。天健会计师事务所（特殊普通合伙）对本次公开发 行新股的募集资金到位情况进行了审验，并于 2022 年 10 月 25 日出具了《验资 报告》（天健验〔2022〕1-119 号）。 （二）募集资金使用和结余情况 1 截至 2024 年 6 月 30 日，公司首次公开发行股票并在创业板上市的募集资金 使用及结存情况如下： | 单位：人民币万元 | | --- | 专项报告 本公司及 ...

一、董事会会议召开情况 北京怡和嘉业医疗科技股份有限公司（以下简称"公司"）第三届董事会第 九次会议于 2024 年 8 月 19 日在公司会议室以现场结合通讯的方式召开，会议通 知已于 2024 年 8 月 9 日以书面、电子邮件方式发出并送达全体董事。本次会议 由公司董事长庄志先生召集并主持。本次会议应出席的董事 9 人，实际出席的董 事 9 人，其中董事崔文立、周明钊、TAN CHING（谈庆）、孙培睿以通讯方式参 加会议。公司监事和高级管理人员列席了本次会议。本次会议的召开符合有关法 律、行政法规、部门规章、规范性文件和《北京怡和嘉业医疗科技股份有限公司 章程》（以下简称"《公司章程》"）的规定。 证券代码：301367 证券简称：怡和嘉业 公告编号：2024-047 北京怡和嘉业医疗科技股份有限公司 第三届董事会第九次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 表决结果：9 票赞成，0 票反对，0 票弃权。 二、董事会会议审议情况 经全体与会董事充分讨论，本次会议审议并通过了如下议案： 1、审议通过《关于公司 2024 年半年度报告 ...

证券代码：301367 证券简称：怡和嘉业 公告编号：2024-048 北京怡和嘉业医疗科技股份有限公司 具体内容详见公司同日披露于巨潮资讯网（www.cninfo.com.cn）上的《2024 年半年度报告》《2024 年半年度报告摘要》。 第三届监事会第九次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 北京怡和嘉业医疗科技股份有限公司（以下简称"公司"）第三届监事会第 九次会议于 2024 年 8 月 19 日在公司会议室以现场结合通讯方式召开，会议通知 已于 2024 年 8 月 9 日以书面、电子邮件方式发出并送达全体监事。会议由公司 监事会主席肖爱军先生召集并主持。本次会议应出席的监事 3 人，实际出席的监 事 3 人，其中孟晓英以通讯方式参加会议。公司董事会秘书列席本次会议。本次 监事会会议的召开符合有关法律、行政法规、部门规章、规范性文件和《北京怡 和嘉业医疗科技股份有限公司章程》的规定。 二、监事会会议审议情况 经全体与会监事充分讨论，本次会议审议并通过了如下议案： 1、审议通过《关于公司 2024 年半 ...

北京怡和嘉业医疗科技股份有限公司 2024 年半年度非经营性资金占用及其他关联资金往来情况汇总表 | | 资金占用方名 | 占用方与上 | 上市公司核算的 | 2024 年期初占 | 年半年度占 2024 | 2024 | 年半年度占 | 年半年 2024 | 年半年 2024 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用 | | 市公司的关 | | | 用累计发生金额 | | 用资金的利息 | 度偿还累计发 | 度期末占用 | 占用形成原因 | 占用性质 | | | 称 | 联关系 | 会计科目 | 用资金余额 | （不含利息） | | （如有） | 生金额 | 资金余额 | | | | 控股股东、实际控制 | | | | | | | | | | | | | 人及其附属企业 | | | | | | | | | | | 非经营性占用 | | 小计 | - | - | - | | | | | | | | - | | 前控股股东、实际控 | | | | | | | | | | | ...

根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》等相关规定，公司应当在每个月的前 3 个交易日内披露截至 上月末的回购进展情况。现将公司回购股份进展情况公告如下： 一、回购公司股份的进展情况 截至 2024 年 7 月 31 日，公司通过股票回购专用证券账户以集中竞价交易方 式回购股份，累计回购股份数量为 604,680 股，占公司目前总股本的 0.67%，回 购的最高成交价为 68.00 元/股，最低成交价为 57.62 元/股，成交总金额为 36,674,841.80 元（不含交易费用）。本次回购符合公司回购股份方案及相关法律 法规的要求。 证券代码：301367 证券简称：怡和嘉业 公告编号：2024-046 北京怡和嘉业医疗科技股份有限公司 关于回购公司股份进展的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 北京怡和嘉业医疗科技股份有限公司（以下简称"公司"）于 2024 年 4 月 11 日召开公司第三届董事会第七次会议和第三届监事会第七次会议，审议通过 《关于回购公司股份方案的议案》。回购股份的实施期 ...

证券代码：301367 证券简称：怡和嘉业 北京怡和嘉业医疗科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |----------------|------------------------------|----------------------------------------------------------| | | | 编号：2024—008 | | | □ 特定对象调研 □ | 分析师会议 | | 投资者关系活动 | □ 媒体采访 □ | 业绩说明会（电话形式） | | 类别 | □ 新闻发布会 | √ 路演活动 | | | √ 现场参观 | | | | □ 其他 | | | 参与单位名称 | 详见附件清单 | | | 时间 | 2024 年 7 月 29 日- 2024 | 年 7 月 30 日 | | 地点 | 北京 | | | 上市公司接待人 | 副总经理兼董事会秘书：杜祎程 | | | 员姓名 | 证券事务代表：刘士岩 | | | | 一、公司简要介绍 | | | | 公司 2001 年成立， | 2003 年第一台多导睡眠检测仪上市，2007 | | ...